Fate Therapeutics (FATE) Upgraded to “Strong-Buy” by BidaskClub

Fate Therapeutics (NASDAQ:FATE) was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Tuesday, January 23rd.

Several other research analysts have also recently issued reports on the company. Zacks Investment Research upgraded Fate Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price objective for the company in a research note on Tuesday, January 9th. Wedbush restated an “outperform” rating and issued a $7.00 price objective on shares of Fate Therapeutics in a research note on Monday, December 18th. HC Wainwright restated a “buy” rating and issued a $7.00 price objective on shares of Fate Therapeutics in a research note on Thursday, October 12th. Piper Jaffray Companies initiated coverage on Fate Therapeutics in a research note on Monday, December 18th. They issued an “overweight” rating and a $10.00 price objective for the company. Finally, Raymond James Financial reiterated a “buy” rating on shares of Fate Therapeutics in a research report on Tuesday, December 12th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Fate Therapeutics presently has a consensus rating of “Buy” and an average price target of $7.71.

Shares of Fate Therapeutics (NASDAQ:FATE) traded up $0.14 during midday trading on Tuesday, reaching $7.99. The company’s stock had a trading volume of 404,967 shares, compared to its average volume of 615,960. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.21 and a current ratio of 7.21. The firm has a market capitalization of $397.66, a P/E ratio of -8.35 and a beta of 2.00. Fate Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $9.78.

A number of hedge funds have recently made changes to their positions in FATE. Northern Trust Corp increased its position in shares of Fate Therapeutics by 968.7% in the second quarter. Northern Trust Corp now owns 368,208 shares of the biopharmaceutical company’s stock valued at $1,193,000 after buying an additional 333,753 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Fate Therapeutics by 164.7% in the second quarter. Bank of New York Mellon Corp now owns 157,546 shares of the biopharmaceutical company’s stock worth $511,000 after acquiring an additional 98,036 shares during the last quarter. TIAA CREF Investment Management LLC acquired a new stake in shares of Fate Therapeutics in the second quarter worth approximately $373,000. OxFORD Asset Management LLP acquired a new stake in shares of Fate Therapeutics in the second quarter worth approximately $303,000. Finally, Vanguard Group Inc. boosted its stake in shares of Fate Therapeutics by 9.4% in the second quarter. Vanguard Group Inc. now owns 1,264,281 shares of the biopharmaceutical company’s stock worth $4,096,000 after acquiring an additional 108,602 shares during the last quarter. Institutional investors own 50.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/14/fate-therapeutics-fate-upgraded-by-bidaskclub-to-strong-buy.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply